Delivering the vision of a world where disease is no longer an insurmountable burden for patients and healthcare professionals would be a phenomenal achievement in the history of medicine.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
